Latest Us Market News

Acusensus Limited has landed its first major automated enforcement contract in the US with Connecticut, marking a significant milestone in its American growth strategy. The five-year deal, valued at US$22.6 million, will see the deployment of AI-enabled speed enforcement technology across work zones.

dorsaVi reports a striking 15-fold increase in US Physical Therapy clinic subscriptions for its ViMove+ product, driven by strong surgeon endorsements and a successful face-to-face training rollout.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Cobram Estate Olives has successfully closed a $6.1 million Share Purchase Plan alongside a $2 million shortfall placement, fueling its US growth ambitions. The capital raise complements a recent $175 million institutional placement, underpinning the company’s strategic farmland acquisitions and olive grove developments in America.

The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

Orthocell has reported a record $3 million revenue for the September quarter, driven by strong sales of its nerve repair product Remplir™ in Australia and Singapore, with early US sales and Canadian market entry poised to accelerate growth.

G50 Corp has completed the acquisition of 100% ownership of its Golconda Project in Arizona, following significant exploration successes that position the company for accelerated development and commercialisation.